Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:33:34.551Z.
Calculation as of: 2026-10-06T16:33:34.551Z.
Quote observation: 2026-10-06T16:30:31.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f4a2befa970cab8c9956b6d8c2bddfeceb0bcb8bde8cbc5a5c0f5a0c0e258424
PE RATIO
N/A
Market Cap
$538.54M
PE Ratio
1200.00
TTM Avg
806.49
3Y Avg
715.80
5Y Avg
715.80
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monopar Therapeutics Inc. (MNPR) | $522.46M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $518.18M | N/A | 0.20 | 0.20 | 0.20 |
| Immix Biopharma, Inc. (IMMX)vs › | $528.79M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $513.33M | N/A | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $536.32M | N/A | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $508.33M | N/A | 12.07 | 12.07 | 12.07 |
| Delcath Systems, Inc. (DCTH)vs › | $538.54M | 1200.00 | 806.49 | 715.80 | 715.80 |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $539.30M | N/A | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $542.14M | N/A | N/A | N/A | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $509.10M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$77.99
Forward EPS (Est.)
$-2.90
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
